Vanderbilt Vaccine Center Archives
Mar. 31, 2022—Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19.
Mar. 9, 2022—Laboratory and administrative personnel at Vanderbilt University Medical Center were honored March 4 for research excellence during the 18th annual Research Staff Awards Ceremony.
Feb. 17, 2022—Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
Oct. 28, 2021— by Bill Snyder A combination of two broadly acting monoclonal antibodies isolated by researchers at Vanderbilt University Medical Center protected non-human primates from ebolavirus disease, which causes severe and often-fatal hemorrhagic fever in humans. Their findings, published this week in the journal Cell, bring closer to development the first clinical therapy effective against all...
Oct. 28, 2021—Vanderbilt's Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases.
Oct. 5, 2021—Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.
Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
Sep. 8, 2021—Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.
Aug. 20, 2021—A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.